Cargando…

Safety of Gadoterate Meglumine (Gd-DOTA) as a Contrast Agent for Magnetic Resonance Imaging: Results of a Post-Marketing Surveillance Study in Japan

Background: Safety is a primary concern with contrast agents used for MRI. If precautions could be taken before the repeated administration of gadolinium-based contrast media, then the awareness and management of adverse reactions would be more efficient. Objectives: To assess the safety and efficac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ishiguchi, Tsuneo, Takahashi, Shoki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2012
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586093/ https://www.ncbi.nlm.nih.gov/pubmed/20945944 http://dx.doi.org/10.2165/11539140-000000000-00000

Ejemplares similares

Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study)
por: Deray, Gilbert, et al.
Publicado: (2012)

The effects of three different contrast agents (Gd-BOPTA, Gd-DTPA, and Gd-DOTA) on brachial plexus magnetic resonance imaging
por: Zhang, Xiaojing, et al.
Publicado: (2021)

Anaphylaxis to gadobutrol and gadoterate meglumine in a patient with low grade astrocytoma
por: Montalvo, Juan Manuel Escobar, et al.
Publicado: (2014)

Gadoterate meglumine decreases ADC values of breast lesions depending on the b value combination
por: Arponen, Otso, et al.
Publicado: (2018)

Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study
por: Soyer, Philippe, et al.
Publicado: (2016)

Safety of gadoterate meglumine in over 1600 children included in the prospective observational SECURE study
por: Chang, De-Hua, et al.
Publicado: (2019)

Lack of evidence of a relationship between magnetic resonance signal intensity changes in the globus pallidus and dentate nucleus, and repeated administrations of gadoterate meglumine in children
por: Lancelot, Eric, et al.
Publicado: (2017)

A Pharmacokinetics, Efficacy, and Safety Study of Gadoterate Meglumine in Pediatric Subjects Aged Younger Than 2 Years
por: Scala, Mario, et al.
Publicado: (2018)

Gadolinium Clearance in the First 5 Weeks After Repeated Intravenous Administration of Gadoteridol, Gadoterate Meglumine, and Gadobutrol to rats
por: Bussi, Simona, et al.
Publicado: (2021)

Comprehensive Speciation Analysis of Residual Gadolinium in Deep Cerebellar Nuclei in Rats Repeatedly Administered With Gadoterate Meglumine or Gadodiamide
por: Strzeminska, Izabela, et al.
Publicado: (2022)

Polymeric Gd-DOTA amphiphiles form spherical and fibril-shaped nanoparticle MRI contrast agents
por: Randolph, Lyndsay M., et al.
Publicado: (2016)

Gadolinium Retention and Clearance in the Diabetic Brain after Administrations of Gadodiamide, Gadopentetate Dimeglumine, and Gadoterate Meglumine in a Rat Model
por: Wang, Shu-ting, et al.
Publicado: (2019)

Breast lesion detection and characterization with contrast‐enhanced magnetic resonance imaging: Prospective randomized intraindividual comparison of gadoterate meglumine (0.15 mmol/kg) and gadobenate dimeglumine (0.075 mmol/kg) at 3T
por: Clauser, Paola, et al.
Publicado: (2018)

Respiratory anomalies associated with gadoxetate disodium and gadoterate meglumine: compressed sensing MRI revealing physiologic phenomena during the entire injection cycle
por: Glessgen, Carl Guillaume, et al.
Publicado: (2021)

Lumazine Synthase Protein Nanoparticle-Gd(III)-DOTA Conjugate as a T(1) contrast agent for high-field MRI
por: Song, YoungKyu, et al.
Publicado: (2015)

Gd-Si Oxide Nanoparticles as Contrast Agents in Magnetic Resonance Imaging
por: Cabrera-García, Alejandro, et al.
Publicado: (2016)

Trivalent Gd-DOTA reagents for modification of proteins
por: Fisher, Martin J., et al.
Publicado: (2015)

MR imaging of hepatocellular carcinoma: prospective intraindividual head-to-head comparison of the contrast agents gadoxetic acid and gadoteric acid
por: Collettini, Federico, et al.
Publicado: (2022)

Anatomic assessment of pulmonary veins and left atrium - comparison of magnetic resonance angiography with gadoteric acid, the blood pool contrast agent B22956/1 and a non-contrast enhanced imaging approach
por: Rona, Szilard, et al.
Publicado: (2011)

Polydisulfide Gd(III) chelates as biodegradable macromolecular magnetic resonance imaging contrast agents
por: Lu, Zheng-Rong, et al.
Publicado: (2006)

Single-Dose Gadoterate Meglumine for 3T Late Gadolinium Enhancement MRI for the Assessment of Chronic Myocardial Infarction: Intra-Individual Comparison with Conventional Double-Dose 1.5T MRI
por: Lim, Jiyeon, et al.
Publicado: (2018)

The Pattern of Use, Effectiveness, and Safety of Gadoteric Acid (Clariscan) in Patients Undergoing Contrast-Enhanced Magnetic Resonance Imaging: A Prospective, Multicenter, Observational Study
por: Moon, Won-Jin, et al.
Publicado: (2021)

Re: Effects of serial macrocyclic-based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium-related dentate nuclei signal increases in unenhanced T1-weighted brain: a retrospective study in 158 multiple sclerosis (MS) patients
por: Raynaud, Jean-Sébastien, et al.
Publicado: (2018)

Effects of the Magnetic Resonance Imaging Contrast Agent Gd-DTPA on Plant Growth and Root Imaging in Rice
por: Liu, Zan, et al.
Publicado: (2014)

In Vitro Longitudinal Relaxivity Profile of Gd(ABE-DTTA), an Investigational Magnetic Resonance Imaging Contrast Agent
por: Varga-Szemes, Akos, et al.
Publicado: (2016)

Biocompatibility of Gd-Loaded Chitosan-Hyaluronic Acid Nanogels as Contrast Agents for Magnetic Resonance Cancer Imaging
por: Gheran, Cecilia Virginia, et al.
Publicado: (2018)

Influence of aging and gadolinium exposure on T1, T2, and T2*-relaxation in healthy women with an increased risk of breast cancer with and without prior exposure to gadoterate meglumine at 3.0-T brain MR imaging
por: Krug, Kathrin Barbara, et al.
Publicado: (2021)

Imaging of Human Insulin Secreting Cells with Gd-DOTA-P88, a Paramagnetic Contrast Agent Targeting the Beta Cell Biomarker FXYD2γa
por: Demine, Stéphane, et al.
Publicado: (2018)

Design and synthesis of chiral DOTA-based MRI contrast agents with remarkable relaxivities
por: Zhang, Junhui, et al.
Publicado: (2023)

Correction: Effects of the Magnetic Resonance Imaging Contrast Agent Gd-DTPA on Plant Growth and Root Imaging in Rice
Publicado: (2015)

Synthesis and evaluation of nanoglobule-cystamine-(Gd-DO3A), a biodegradable nanosized magnetic resonance contrast agent for dynamic contrast-enhanced magnetic resonance urography
por: Xu, Rongzuo, et al.
Publicado: (2010)

Gd(DOTAlaP): Exploring the Boundaries of Fast Water Exchange in Gadolinium-Based Magnetic Resonance Imaging Contrast Agents
por: Boros, Eszter, et al.
Publicado: (2014)

Gd(3+)-DTPA-Meglumine-Anionic Linear Globular Dendrimer G1: Novel Nanosized Low Toxic Tumor Molecular MR Imaging Agent
por: Darvish Mohamadi, Tahmineh, et al.
Publicado: (2013)

Gd(III)-DOTA-modified sonosensitive liposomes for ultrasound-triggered release and MR imaging
por: Jung, Suk Hyun, et al.
Publicado: (2012)

Novel Gd Nanoparticles Enhance Vascular Contrast for High-Resolution Magnetic Resonance Imaging
por: Bui, Tot, et al.
Publicado: (2010)

Revisiting the factors influencing the magnetic resonance contrast of Gd(2)O(3) nanoparticles
por: Liu, Yanyue, et al.
Publicado: (2021)

DOTAREM (DOTA)–Gold-Nanoparticles: Design, Spectroscopic Evaluation to Build Hybrid Contrast Agents to Applications in Nanomedecine
por: Khan, Memona, et al.
Publicado: (2022)

Gd and Eu Co-Doped Nanoscale Metal–Organic Framework as a T(1)–T(2) Dual-Modal Contrast Agent for Magnetic Resonance Imaging
por: Wang, Geoffrey D., et al.
Publicado: (2016)

Contrast agents in dynamic contrast-enhanced magnetic resonance imaging
por: Yan, Yuling, et al.
Publicado: (2017)

A liposomal Gd contrast agent does not cross the mouse placental barrier
por: Shetty, Anil N., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_om4uq2ltpljah41t99pnbent80